President Biden will convene the UN General Assembly’s virtual COVID-19 summit today—and we’re here to remind you that sharing vaccines, not weakening IP protections, is how we get the world vaccinated.
Breaking news: President Biden is expected to kick off the summit by announcing the U.S. will buy 500 million more vaccine doses to donate to countries in need, bringing the total to 1.1 billion doses, according to reports.
Mark your calendar for September 2022—Biden’s deadline to vaccinate 70% of the world, a target he’s expected to ask leaders to commit to today, per POLITICO Pulse.
To get there, we need to share—but that’s easier said than done, due to U.S. and global trade restrictions, supply chain bottlenecks, and a need for more funding for COVAX.
BIO has proposed a solution:COVID Global Strategy for Harnessing Access Reaching Everyone (SHARE) Program, which would ensure vaccine supply and access as well as strengthen and support health care systems in low- and middle-income countries. (And it seems like the administration is paying attention.)
What won’t work? A waiver of IP protections,as we’ve explained. (POLITICO Pulse says this is “not expected to be featured high on the agenda” today.)
“No expert seriously thinks suspending IP protections will boost vaccine supply,” when production is already at capacity, says Gary Locke, former U.S. Commerce Secretary, Washington State Governor, and U.S. Ambassador to China, in a recent Seattle Times op-ed. “It would take years for new companies to learn to make the vaccines and build specialized factories.”
The bottom line: The U.S. and other wealthy nations need “to do the hard work of expanding manufacturing capacity and distributing vaccines,” he concludes.
Listen: BIO President and CEO Dr. Michelle McMurry-Heath spoke about this topic (and others) with World Trade Organization (WTO) Director-General Dr. Ngozi Okonjo-Iweala—listen here.
More Health Care News:
Biopharma Dive: Second dose of J&J's coronavirus vaccine increases protection, company says
“Summary results from an international Phase 3 trial run by J&J showed an additional shot, given eight weeks after the first, resulted in an estimated 75% protection against moderate to severe COVID-19, compared to placebo. Looking only at study participants in the U.S., J&J reported a higher efficacy estimate of 94%, but that figure was based on far fewer cases than the overall rate.”